Boston Scientific acquires for $950 million 78% of Preventice Solutions, developer of the FDA-approved BodyGuardian® heart monitoring mobile app. Boston Scientific already owns the remaining 22% of the company. The deal is expected to close by mid-2021.
Boston Scientific acquires for $950 million 78% of Preventice Solutions, developer of the FDA-approved BodyGuardian® heart monitoring mobile app. Boston Scientific already owns the remaining 22% of the company. The deal is expected to close by mid-2021. 
English (US) 